Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TAK-121, PTG-300
Rusfertide · 2 trials · 1 indication
Response is defined as the absence of phlebotomy eligibility. Phlebotomy eligibility is defined as: A confirmed hematocrit ≥45%, which is ≥3% (absolute) higher than the baseline hematocrit or hematocrit ≥48%. Confirmation is defined as 2 consecutive hematocrit assessments that are ≥45% and at least 3% higher than the baseline hematocrit.
| Arm | Type | Description |
|---|---|---|
| Rusfertide | EXPERIMENTAL | Participants will receive rusfertide (TAK-121), subcutaneously (SC) once weekly for 52 weeks. |
| Name | Type | Description |
|---|---|---|
| Rusfertide | DRUG | Rusfertide injections administered SC. |
* Inclusion Criteria 1. Chinese male and female participants aged 18 years or older at the time of signing of informed consent. 2. Participant understands the trial procedures, is willing and able to adhere to trial requirements, and agrees to participate in the trial by providing written infor...
Top 6 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Bomedemstat |
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE2 | Rusfertide |
| Agios Pharmaceuticals, Inc. | AGIO | 1 | PHASE2 | AG-236 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
Rusfertide is an investigational small molecule being studied for the treatment of Polycythemia Vera, a hematologic condition. It is currently in Phase 2 clinical development and has not been approved by the FDA. Rusfertide is being evaluated in adult patients with Polycythemia Vera.
Rusfertide targets hepcidin, a peptide hormone that regulates iron metabolism. By modulating hepcidin, Rusfertide may help control red blood cell production in Polycythemia Vera. It is classified as a -tide (peptide) modality, though it is a small molecule.
Rusfertide is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting Phase 2 clinical trials for Rusfertide in Polycythemia Vera. Takeda is responsible for the drug's clinical development program.
Rusfertide is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The drug has been granted Priority Review designation by the FDA, which may expedite the review process if it reaches that stage. Currently, Rusfertide is being studied in clinical trials.
Rusfertide is being studied in two Phase 2 clinical trials. NCT07765602 is a study in adults with Polycythemia Vera in China, with an enrollment of 24 participants, and is not yet recruiting. NCT07648030 is a study in Japanese adults with Polycythemia Vera, enrolling 9 participants, and is currently recruiting.
No, Rusfertide is not the same as hepcidin. Rusfertide is a drug that targets hepcidin, a peptide hormone involved in iron regulation. Rusfertide is a small molecule that modulates hepcidin activity, potentially affecting red blood cell production in Polycythemia Vera.